Dr. Glick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Abramson Cancer Ctr of the Univ of Penn; PCAM, Ste 3-300S
Philadelphia, PA 19104Phone+1 215-662-6334Fax+1 215-662-4370
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1973 - 1974
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1971 - 1973
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1969 - 1971
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1969
- Princeton UniversityA.B., Magna Cum Laude, 1965
Certifications & Licensure
- PA State Medical License 1974 - 2024
- FL State Medical License 2013 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Philadelphia Magazine Castle Connolly, 2004-2014
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) Start of enrollment: 2014 Jan 24
Publications & Presentations
PubMed
- 270 citationsComparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's LymphomaLeo I. Gordon, David P. Harrington, Janet Andersen, Joseph P. Colgan, John H. Glick
The New England Journal of Medicine. 1992-11-05 - 100 citationsA phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (I...Richard I. Fisher, Ellen R. Gaynor, S. Dahlberg, M. M. Oken, T. M. Grogan
Annals of Oncology. 1994-01-01 - 249 citationsChemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484Sandra J. Horning, Edie Weller, Kyung Mann Kim, John D. Earle, Michael J. O'connell
Journal of Clinical Oncology. 2004-08-01
Journal Articles
- Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma; a study by the Eastern Co-operative Onco...Wiernik PH, Hong F, Glick JH, Bennett JM, Leukemia Lymphoma, 1/1/2009
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancerGoldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn JH and Panel Members, Annals of Oncology, 1/1/2009
- Primary Mucosa-associated Tissue Lymphoma of the BreastRajendran RR, Palazzo, JP, Schwartz GF, Glick JH, Solin L, Clinical Breast Cancer, 1/1/2008
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Fifteen-Year Results of Breast-Conserving Surgery and Definitive Irradiation for Stage I and II Breast Carcinoma: The University of Pennsylvania ExperienceSantiago RJ, Wu L, Harris E, Fox K, Schultz D, Glick JH, Solin LJ, American Society of Clinical Oncology, 38th Annual Meeting, Orlando, FL, 5/1/2002
- A Phase I/II dose escalating trial of liposomal doxorubicin (TLCD-99, Myocet) in combination with paclitaxel (Taxol, T) for patients with metastatic breast cancerWelles L, Miller WH Jr, Fox K, Batist G, Glick JH, DeMichele A, American Society of Clinical Oncology, Orlando, FL, 1/1/2002
- Racial differences in hematologic tolerability of adjuvant chemotherapy in breast cancer patientsDeMichele A, Smith K, Wray L, Klein-Cabral M, Fox K, Schuchter L, Glick JH, American Society of Clinical Oncology, Orlando, FL, 1/1/2002
- Join now to see all
Lectures
- Adjuvant Therapy for Early Breast CancerMultiple Locations, 2001, 2004, 2007, 2011 - 1/1/2011
- Systemic Therapy for Breast Cancer1/1/2002
- Breast Cancer: Recent AdvancesNew Brunswick, NJ - 1/1/2002
- Join now to see all
Press Mentions
- John Glick to Retire from Penn MedicineJune 4th, 2021
- An Inspired Life Sparks Generosity, Innovation and HopeNovember 21st, 2018
- Shift in Treating Breast Cancer Is Under DebateMay 12th, 2006
- Join now to see all
Grant Support
- Senior LeadershipNational Cancer Institute2005–2009
- Program LeadersNational Cancer Institute2005–2009
- Planning And EvaluationNational Cancer Institute2005–2009
- Developmental FundsNational Cancer Institute2005–2009
- Abramson Cancer Center Of The U Of P Core Support GrantNational Cancer Institute2005–2006
- The University Of Pennsylvania Cancer Center Core GrantNational Cancer Institute2000–2004
- Core--Protocol Specific Oncology SupportNational Cancer Institute1997–1999
- Core--Developmental FundsNational Cancer Institute1997–1999
- Cancer CenterNational Cancer Institute1995–1999
- Cancer Research Training ProgramNational Cancer Institute1991–1997
- Eastern Cooperative Oncology GroupNational Cancer Institute1985–1996
- University Of Pennsylvania Can Ctr Support GrantNational Cancer Institute1994
- OncologyNational Cancer Institute1994
- University Of Pennsylvania Cancer Center Support GrantNational Cancer Institute1986–1993
- Cancer Center Support GrantNational Cancer Institute1988–1990
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: